Submitted:
27 April 2023
Posted:
28 April 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
Data Source
Reporting and Outcome
Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Funding
Institutional Review Board Statement
Data Availability Statement
Conflicts of Interest
References
- Borrelli, M.; Corcione, A.; Castellano, F.; Fiori Nastro, F.; Santamaria, F. Coronavirus Disease 2019 in Children. Front Pediatr. 2021, 9, 668484. [Google Scholar] [CrossRef]
- Leidman, E.; Duca, L.M.; Omura, J.D.; Proia, K.; Stephens, J.W.; Sauber-Schatz, E.K. COVID-19 Trends Among Persons Aged 0-24 Years - United States, March 1-December 12, 2020. MMWR Morb Mortal Wkly Rep. 2021, 70, 88–94. [Google Scholar] [CrossRef]
- Graff, K.; Smith, C.; Silveira, L.; Jung, S.; Curran-Hays, S.; Jarjour, J.; Carpenter, L.; Pickard, K.; Mattiucci, M.; Fresia, J.; McFarland, E.J.; Dominguez, S.R.; Abuogi, L. Risk Factors for Severe COVID-19 in Children. Pediatr Infect Dis J. 2021, 40, e137–e145. [Google Scholar] [CrossRef] [PubMed]
- Rowley, A.H. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol. 2020, 20, 453–454. [Google Scholar] [CrossRef] [PubMed]
- Clark, B.C.; Sanchez-de-Toledo, J. ; Bautista-Rodriguez; et al. Cardiac abnormalities seen in pediatric patients during the SARS-CoV2 pandemic: an international experience. J Am Heart Assoc 2020, 9, e018007. [Google Scholar] [PubMed]
- Available online: https://www.gov.pl/web/koronawirus/wykaz-zarazen-koronawirusem-sars-cov-2.
- Derespina, K.R.; Kaushik, S.; Plichta, A.; Conway EEJr Bercow, A.; Choi, J.; et al. Clinical manifestations and outcomes of critically ill children and adolescents with coronavirus disease 2019 in New York City. J Pediatr. 2020, 226, 55–63e2. [Google Scholar] [CrossRef]
- García-Salido; et al. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit Care. 2020, 24, 666. [CrossRef]
- Shekerdemian, L.S.; et al. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. JAMA Pediatr. 2020, 174, 868–873. [Google Scholar] [CrossRef]
- Graff, K.; Smith, C.; Silveira, L.; et al. Risk factors for severe COVID-19 in children. Pediatr Infect Dis J 2021, 40, e137–45. [Google Scholar] [CrossRef]
- Bellino, S.; Punzo, O.; Rota, M.C.; Del Manso, M.; Urdiales, A.M.; Andrianou, X.; et al. COVID-19 disease severity risk factors for pediatric patients in Italy. Pediatrics. 2020, 146, e2020009399. [Google Scholar] [CrossRef]
- Tang, Y.; Li, W.; Baskota, M.; Zhou, Q.; Fu, Z.; Luo, Z.; Shi, Y.; Chen, Y.; Liu, E. Multisystem inflammatory syndrome in children during the coronavirus disease 2019 (COVID-19) pandemic: a systematic review of published case studies. Transl Pediatr. 2021, 10, 121–135. [Google Scholar] [CrossRef]
- Hoste, L.; Van Paemel, R.; Haerynck, F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur J Pediatr. 2021, 180, 2019–2034. [Google Scholar] [CrossRef]
- Krzych, Ł.; Bartkowska-Śniatkowska, A.; Knapik, P.; Zielińska, M.; Maciejewski, D.; Cettler, M.; Owczuk, R.; Kusza, K. Guidelines of the Polish Society of Anaesthesiology and Intensive Therapy defining the rules of qualification and criteria for admitting patients to anaesthesiology and intensive care units. Anaesthesiol Intensive Ther. 2022, 54, 219–225. [Google Scholar] [CrossRef] [PubMed]
- Hoang, A.; Chorath, K.; Moreira, A.; Evans, M.; Burmeister-Morton, F.; Burmeister, F.; et al. COVID-19 in 7780 pediatric patients: a systematic review. E Clin Med. 2020, 24, 100433. [Google Scholar] [CrossRef] [PubMed]
- Christophers, B.; Gallo Marin, B.; Oliva, R.; Powell, W.T.; Savage, T.J.; Michelow, I.C. Trends in clinical presentation of children with COVID19: a systematic review of individual participant data. Pediatr Res. 2020. [CrossRef]
- Mania, A.; Faltin, K.; Mazur-Melewska, K.; Małecki, P.; Jończyk-Potoczna, K.; et al, M.; et al. Clinical Picture and Risk Factors of Severe Respiratory Symptoms in COVID-19 in Children. Viruses. 2021, 13, 2366. [Google Scholar] [CrossRef]
- Henry, B.M.; Benoit, S.W.; de Oliveira, M.H.S.; Hsieh, W.C.; Benoit, J.; Ballout, R.A.; Plebani, M.; Lippi, G. Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): A pooled analysis and review. Clin Biochem. 2020, 81, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Marjot, T.; Webb, G.J.; Barritt, A.S., 4th; et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021, 18, 348–364. [Google Scholar] [CrossRef]
- Oualha, M.; Bendavid, M.; Berteloot, L.; Corsia, A.; Lesage, F.; Vedrenne, M.; Salvador, E.; Grimaud, M.; Chareyre, J.; de Marcellus, C.; et al. Severe and fatal forms of COVID-19 in children. Arch. Pédiatrie. 2020, 27, 235–238. [Google Scholar] [CrossRef] [PubMed]
- Kompaniyets, L.; Agathis, N.T.; Nelson, J.M.; Preston, L.E.; Ko, J.Y.; Belay, B.; Pennington, A.F.; Danielson, M.L.; DeSisto, C.L.; Chevinsky, J.R.; et al. Underlying Medical Conditions Associated With Severe COVID-19 Illness Among Children. JAMA Netw. Open. 2021, 4, e2111182. [Google Scholar] [CrossRef]
- Choi, J.H.; Choi, S.H.; Yun, K.W. Risk Factors for Severe COVID-19 in Children: A Systematic Review and Meta-Analysis. J Korean Med Sci. 2022, 37, e35. [Google Scholar] [CrossRef]
- Delahoy, M.J.; Ujamaa, D.; Whitaker, M.; O'Halloran, A.; Anglin, O.; et al. Hospitalizations Associated with COVID-19 Among Children and Adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021. MMWR Morb Mortal Wkly Rep. 2021, 70, 1255–1260. [Google Scholar] [CrossRef]
- Bartkowska-Śniatkowska, A.; Byrska-Maciejasz, E.; Cettler, M.; Damps, M.; Jarosz, K.; et al. Guidelines regarding ineffective maintenance of organ functions (futile therapy) in paediatric intensive care units. Anaesthesiol Intensive Ther. 2021, 53, 369–375. [Google Scholar] [CrossRef]
- Damps, M.; Gajda, M.; Stołtny, L.; Kowalska, M.; Kucewicz-Czech, E. Limiting futile therapy as part of end-of-life care in intensive care units. Anaesthesiol Intensive Ther. 2022, 54, 279–284. [Google Scholar] [CrossRef]
- Kucewicz-Czech, E.; Damps, M. Triage during the COVID-19 pandemic. Anaesthesiol Intensive Ther. 2020, 52, 312–315. [Google Scholar] [CrossRef]
- Simon, K.; Rorat, M.; Janocha-Litwin, J.; Pazgan-Simon, M. SARS-CoV-2 infection: etiopathogenesis, clinical picture, current therapeutic options – the author’s observations. NOWOTWORY J Oncol 2021, 71, 38–41. [Google Scholar] [CrossRef]
- Adeyinka, A.; Bailey, K.; Pierre, L.; Kondamudi, N. COVID 19 infection: Pediatric perspectives. J Am Coll Emerg Physicians Open. 2021, 2, e12375. [Google Scholar] [CrossRef]
- Lippi, G.; Plebani, M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med. 2020, 58, 1063–1069. [Google Scholar] [CrossRef] [PubMed]
- Potere, N.; Batticciotto, A.; Vecchié, A.; Porreca, E.; Cappelli, A.; Abbate, A.; Dentali, F.; Bonaventura, A. The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol. 2021, 17, 601–618. [Google Scholar] [CrossRef] [PubMed]
- Verdecchia, P. , Cavallini C., Spanevello A., Angeli F.: The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med 2020, pii, S0953-6205(20)30151-5. [CrossRef]
- Yang, X.; Yu, Y.; Xu, J.; Shu, H.; Xia, J.; Liu, H.; et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020, 8, 475–481. [Google Scholar] [CrossRef] [PubMed]
- Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X.; et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020, 382, 1708–1720. [Google Scholar] [CrossRef]
- Kim, L.; Whitaker, M.; O’Halloran, A.; et al. COVID-NET Surveillance Team. Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 - COVID-NET, 14 States, March1-July 25, 2020. MMWR Morb Mortal Wkly Rep. 2020, 69, 1081–1088. [Google Scholar] [PubMed]
- Götzinger, F.; Santiago-García, B.; Noguera-Julián, A.; Lanaspa, M.; Lancella, L.; Calò Carducci, F.I.; et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 2020, 4, 653–661. [Google Scholar] [CrossRef] [PubMed]
- Swann, O.V.; Holden, K.A.; Turtle, L.; Pollock, L.; Fairfield, C.J.; Drake, T.M.; et al. Clinical characteristics of children and young people admitted to hospital with COVID-19 in United Kingdom: prospective multicentre observational cohort study. BMJ 2020, 370, m3249. [Google Scholar] [CrossRef]
| Hospital name, city | Number of patients |
|---|---|
| Upper Silesian Child Health Centre, Katowice | 9 |
| University Child Hospital, Lublin | 9 |
| University Hospital, Poznan | 7 |
| University Hospital Nr 1,Szczecin | 4 |
| University Child Hospital, Białystok | 4 |
| University Hospital, Rzeszów | 3 |
| Copernicus Hospital, Gdansk | 2 |
| University Clinical Centre of the Medical University of Warsaw | 2 |
| University Children’s Hospital of Cracow | 2 |
| University Clinical Hospital in Wroclaw | 2 |
| Children's Memorial Health Institute, Warsaw | 1 |
| Survived (n=27) | Died (n=18) | p | |
|---|---|---|---|
|
Sex Females Males |
n=9 n=18 |
n=11 n=7 |
0.125 |
| Age [months] mean ± SD, median | 73.15 ± 75.93; 30.5 | 71.82 ± 75.18; 26 | 0.654 |
|
BMI Underweight, n, % Normal, n, % Obesity, n, % |
13 (50.00%) 12 (46.15%) 1 (3.85%) |
7 (38.89%) 6 (33.34%) 5 (27.77%) |
0.748 |
|
Time from positive test to hospitalization in the ICU [days] mean ± SD, median |
2.24 ± 3.73; 1 |
5.06 ± 10.65; 1 |
0.608 |
|
Comorbidities 1. Neurological disorders, n, % 2. Immobilisation, n, % 3. Immunosuppressive drugs, n, % 4. Congenital heart diseases, n, % 5. Respiratory failure, n, % 6. None, n, % |
15 (55,55%) 10 (37,03%) 2 (7,4%) 3 (11,11%) 5 (18,5%) 5 (18,5%) |
5 (27,77%) 3 (16,66%) 2 (11,11%) 6 (33,33%) 7 (38,88%) - |
0.227 |
|
Where the patient came from Covid-19 ward, n, % Emergency Room, n, % Home, n, % Pediatric Ward, n, % Other ICU, n, % Operating block, n, % |
6 (22.22%) 5 (18.53%) 5 (18.52%) 9 (33.33%) 1 (3.70%) 1 (3.70%) |
6 (33.33%) 2 (11.11%) 4 (22.22) 3 (16.67%) 2 (11.11%) 1 (5.56%) |
0.691* |
| Oxygen therapy, n, % | 7 (25,92%) | 18 (100%) | 0.018* |
| Mechanical ventilation, n, % | 20 (74,07%) | 18 (100%) | |
| Circulatory failure | 15 (57,69%) | 12 (66,67%) | 0,54 |
| Hospitalization time [days] mean ± SD, median | 16.56±13.60, 12 | 10.82±7.02, 11 | 0.330 |
| Mortality, n, % study group | 18 (40%) |
| Parameter (mean ± SD; median) | Survived | Died | P in U-Mann Whitney test |
| pH first measurement | 7.33±0.13; 7.36 | 7.34±0.09; 7.31 | 0.763 |
| pO2 first measurement [mmHg] | 103.84±53.61; 84.4 | 72.75±49.49; 54.0 | 0.018* |
| pCO2 first measurement [mmHg] | 52.91±24.49; 47.0 | 51.68±21.85; 45.5 | 0.990 |
|
Arterial oxygen saturation first measurement |
92.39±7.91; 95.0 | 78.43±20.92; 84.0 | 0.018* |
| Fi02 | 0.65±0.30; 0.5 | 0.89±0.19; 1.0 | 0.020* |
| Oxygen index- 1st day [mmHg] | 207.73±137.32; 172.5 | 121.82±147.37; 57.6 | 0.003* |
| Oxygen index- 3rd day [mmHg] | 232.29±179.71; 180.0 | 145.07±142.96; 96.0 | 0.006* |
| Oxygen index- 5th day [mmHg] | 229.86±178.88; 158.5 | 143.87±135.10; 84.5 | 0.124 |
| Lung injury score- 1st day | 2.52±1.81; 2.0 | 2.73±1.35; 3.0 | 0.047* |
| Lung injury score- 3rd day | 2.62±1.44; 2.3 | 2.47±1.03; 3.0 | 0.939 |
| Lung injury score- 5th day | 2.23±1.29, 2.15 | 2.59±0.87; 3.0 | 0.873 |
| pSOFA- 1st day | 6.22±2.88; 5.5 | 9.38±3.12; 10.0 | 0.012* |
| pSOFA- 3rd day | 6.19±3.41; 5.0 | 10.50±3.10; 10.5 | 0.007* |
| pSOFA- 5th day | 5.78±3.15; 5.0 | 11.50±4.09; 12.0 | 0.001* |
| WBC- 1st day [× 109 per L] | 10.86±7.17; 9.69 | 10.81±10.10; 6.45 | 0.614 |
| PLT- 1st day [× 109 per L] | 202.82±113.68; 197.0 | 207.64±171.74; 142.0 | 0.832 |
| HGB- 1st day [g/dL] | 10.91±3.75; 9.8 | 10.94±1.51; 10.5 | 0.178 |
| Procalcitonin- 1st day [ng/ml] | 7.21±8.96; 2.34 | 6.64±17.33; 0.37 | 0.118 |
| C-reactive protein- 1st day [mg/l] | 58.85±106.87; 12.48 | 57.75±77.61; 17.4 | 0.365 |
| D-dimer- 1st day [ng FEU/ml] | 3573.71±4953.15; 1900.0 | 2813.75±3343.10; 1485.5 | 0.561 |
| Creatynine- 1st day [mg/dl] | 0.59±0.87; 0.26 | 0.47±0.32; 0.37 | 0.456 |
| Urea- 1st day [mg/dl] | 48.70±54.35; 32.0 | 27.23±18.06; 24.0 | 0.217 |
| Ferritine [µg/l] | 2307.18±6288.94; 193.0 | 1112.53±1431.25; 430.75 | 0.433 |
| LDH [U/l] | 687.78±575.99; 434.5 | 817.23±678.26; 505.0 | 0.232 |
| Troponin [pg/ml] | 49.90±62.55; 24.6 | 950.94±2293.97; 204.0 | 0.089 |
| IL-6 [pg/ml] | 74.22±149.74; 18.085 | 95.12±124.83; 51.27 | 0.798 |
| Lactate- 1st day [mmol/l] | 3.03±4.23; 1.1 | 17.76±48.76; 3.26 | 0.070 |
| AST- 1st day [IU/l] | 83.04±132.24; 41.0 | 112.89±139.33; 66.5 | 0.028* |
| ALT- 1st day [IU/l] | 75.87±176.89; 25.0 | 118.22±281.05; 38.5 | 0.351 |
| Number (%) | Survived (n=27) | Died (n=18) | P in chi-square test |
|---|---|---|---|
| COVID-19 convalescent plasma | 7(26.92%) | 4 (23.53%) | 0.803 |
| Tocilizumab | 2 (8%) | 1 (5.88%) | 0.793 |
| Remdesivir | 5 (19.23%) | 6 (33,33%) | 0.288 |
| Steroid therapy | 27 (100%) | 16 (88,88%) | 0.076 |
| Anticoagulants | 24 (92.30%) | 13 (72,22%) | 0.073 |
| Immunoglobulins | 7 (25,92%) | 8 (44,44%) | 0.196 |
| Antispasmodics | 11 (40,74%) | 10 (55,55%) | 0.329 |
| Parameter [mean ± SD; median] |
Ventilated patients who survived (N=21) |
Ventilated patients who died (N=17) |
P value |
|---|---|---|---|
|
Time from positive test to hospitalization in the ICU [days] |
1,63 ± 2,63; 2,13 | 5,24 ± 10,59; 1,0 | 0,247 |
|
Oxygen index in the1st day [mmHg] |
206.72 ± 147.89; 153.0 | 122.70 ± 151.86; 56.0 | 0.007* |
|
Oxygen index in the 3rdday [mmHg] |
232.29 ± 179.71; 180.0 | 145.07 ± 142.96; 96.0 | 0.086 |
|
Oxygen index in the 5thday [mmHg] |
229.86 ± 178.88; 158.5 | 143.87 ± 135.10; 84.5 | 0.124 |
| Lung injury score in the 1st day | 2.52 ± 1.81; 2.0 | 3.0 ± 1.35; 3.0 | 0.106 |
| Lung injury score in the 3rd day | 2.62 ± 1.44; 2.3 | 2.47 ± 1.03; 3.0 | 0.909 |
| Lung injury score in the 5th day | 2.213±1.34,2.1 | 2.59 ± 0.87; 3.0 | 0,48 |
| pSOFA in the 1st day | 6.62 ± 2.78; 6.0 | 9.17 ± 3.16; 9.0 | 0.043* |
| pSOFA in the 3rd day | 6.47 ± 3.33; 5.0 | 10.33 ± 3.24; 10.0 | 0.020* |
| pSOFA in the 5th day | 6.0 ± 3.10; 5.0 | 11.22 ± 4.24; 11.0 | 0.005* |
|
WBC in the 1st day [× 109 per L] |
10.86 ± 7.17; 9.69 | 18.22 ± 10.10; 6.45 | 0.868 |
|
PLT in the 1st day [× 109 per L] |
202.82 ± 113.68; 197.0 | 162.0 ± 171.74; 142.0 | 0.985 |
|
HGB in the 1st day [g/dl] |
10.91 ± 3.75; 9.8 | 10.2 ± 1.51; 10.5 | 0.126 |
|
Procalcitonin in the 1st day [ng/ml] |
7.21 ± 8.96; 2.34 | 0.6 ± 17.33; 0.37 | 0.118 |
|
C-reactive protein in the 1st day [mg/l] |
58.85 ± 106.87; 12.48 | 13.73 ± 77.61; 17.4 | 0.235 |
|
D-dimer in the 1st day [ng FEU/ml] |
3573.71 ± 4953.15; 1900.0 | 429.0 ± 3343.09, 1485.5 | 0.897 |
|
Creatynine in the 1st day [mg/dl] |
0.59 ± 0.87; 0.26 | 0.27 ± 0.32; 0.37 | 0.231 |
|
Urea in the 1st day [mg/dl] |
48.70 ± 54.35; 32.0 | 8.0 ± 18.06; 24.0 | 0.362 |
|
Ferritine [µg/l] |
1837.64 ± 5594.13; 152.65 | 1112.53 ± 1431.25; 430.75 | 0.650 |
| LDH [U/l] | 652.88 ± 526.68; 489.0 | 817.23 ± 678.26; 505.0 | 0.257 |
| Troponin [pg/ml] | 41.65 ± 59.86; 16.95 | 384.0 ± 2293.97; 205 | 0.130 |
| NT proBNP [pg/ml] | 10565.47 ± 15675.56; 2100.0 | 918.5 ± 441.94; 918.5 | 0.932 |
| IL-6 [pg/ml] | 74.22 ± 149.74; 18.08 | 7.54 ± 124.83; 51.27 | 0.798 |
| Lactate [mmol/l] | 2.95 ± 3.80; 1.7 | 17.76 ± 48.76; 3.26 | 0.092 |
| AST in the 1st day [IU/l] | 81.90± 135.85; 41.0 | 117.23± 142.36; 77.0 | 0.039* |
| ALT in the 1st day [IU/l] | 72.0 ± 166.48; 25.5 | 39.0 ± 281.05; 38.5 | 0.217 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
